ST. GALLEN, Switzerland, Aug. 28, 2023 /PRNewswire/ — CSL Vifor is pleased to announce that the European Society of Cardiology (ESC) have upgraded recommendations in the ESC 2023 guidelines for the treatment of iron deficiency acute and chronic HF with IV iron supplementation, including Ferinject®. The guidelines include higher level of recommendations and address a […]
Author: Ken Dropiewski
ADVENT Study of the FARAPULSE™ Pulsed Field Ablation System Meets Primary Efficacy and Safety Endpoints
MARLBOROUGH, Mass. and AMSTERDAM, Aug. 27, 2023 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE™ Pulsed Field Ablation (PFA) System*, a nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation (AF). The study is the first […]
AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023
THOUSAND OAKS, Calif., Aug. 26, 2023 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran […]
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
EAST HANOVER, N.J., Aug. 28, 2023 /PRNewswire/ — Novartis today announced new long-term data from ORION-8, a Phase III open-label extension of ORION-9, ORION-10, ORION-11 and ORION-3 trials. The data demonstrated that with twice-yearly* dosing, Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six years in patients […]
Nectero Medical Receives FDA Fast Track Designation for Nectero EAST® System
TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System to treat patients with infrarenal AAAs, maximum diameter 3.5 – […]
Endologix Announces that Lucas Buchanan Joins Board of Directors
RVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Lucas Buchanan has been appointed to the Endologix Board of Directors. “We are thrilled to welcome Lucas to our Board of Directors” […]
HeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation
Southlake, TX, Aug. 24, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces that its MyoVista® wavECGTM has been selected by PanaceaFlo Ltd to […]
Philips integrates AI in cardiac ultrasound and across cardiac care at ESC 2023
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how it integrates AI in cardiac ultrasound and across cardiac care to help improve clinical confidence and increase efficiency. Center-stage at the European Society of Cardiology (ESC, Aug. 25-28, Amsterdam) Congress is the portable Philips […]
CareSimple and UCSF Announce Clinical Trial on Equity in Remote Hypertension Self-Management
UCSF Researchers to Leverage Industry-Leading RPM Platform for Remote Monitoring for Equity in Advancing Control of Hypertension (REACH) Study NORTH PALM BEACH, Fla., Aug. 24, 2023 /PRNewswire/ — CareSimple, the platform simplifying remote patient monitoring (RPM) for virtually all patients has announced a partnership with the University of California San Francisco (UCSF) to conduct the […]
Medtronic issues statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System
DUBLIN, Aug. 23, 2023 /PRNewswire/ — Today, Medtronic announced the outcome of the U.S. Food & Drug Administration (FDA) Circulatory System Devices Panel (CSDP) meeting to review data presented in support of the Medtronic Symplicity Spyral™ Renal Denervation (RDN) System. The panel Committee voted unanimously (13-0) on safety and in favor (7-6) […]
Recent
Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
Medera Announces Independent Data Monitoring Committee (DMC) Recommends Continued Advancement of Lead HFpEF Gene Therapy Program
Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders
Popular
- No commented posts yet